Compare ARK Genomic Revolution ETF (ARKG) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Oracle Corporation — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while Oracle Corporation trades at $140.15 (market cap $405.11B). The key difference: Oracle Corporation pays a 1.42% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Oracle Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | ORCL | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $328.33 |
52-Week Low | $23.09 | $136.39 |
Market Cap | — | $405.11B |
Enterprise Value | — | $534.36B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Oracle Corporation (ORCL) trades at $140.68, down 2.49% today, amid mixed technical signals with a bearish overall trend. Fundamentally, the company shows strong profitability with 25.37% net income margin and consistent earnings beats in recent quarters. Revenue growth continues with $57.4B in FY2025, while analyst consensus remains bullish with a $259 price target. Recent news highlights Oracle's positioning in AI infrastructure and partnership developments with OpenAI.
Oracle presents a compelling investment case with strong fundamentals and AI growth potential, though technical weakness and high valuation metrics warrant caution. The stock offers upside to analyst targets but faces execution risks in competitive cloud markets and substantial debt levels that could pressure returns if interest rates remain elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
